A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75098 Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors
Latest Information Update: 13 Nov 2025
At a glance
- Drugs BGB-43395; Fulvestrant
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors BeOne Medicines
Most Recent Events
- 13 Nov 2025 New trial record